Nitto Pharma will exhibit at Bio Japan 2018, Pacifico Yokohama, 10-12 October 2018

Nitto Pharma will sponsor a seminar on 10 October 2018 at Bio Japan 2018. Details about the exhibition booth and seminar Place: PACIFICO Yokohama, PACIFIC Convention Plaza Yokohama, 1-1-1, Minato Mirai, Nishi-ku, Yokohama, Japan. Nitto Pharma Booth: C-29 Nitto Pharma sponsored seminar: 【S-2】NITTO PHARMACEUTICAL INDUSTRIES, LTD Theme: ”Postbiotics” for health -Analysis and application of functional

Continue reading »
NITTO PHARMA SPONSORS AAAS SCIENCE WEBINAR ON 8 AUGUST 2018

The theme of the webinar is: “The new era of postbiotics: Gut microbiome-derived lipid metabolites for health and wellness”, and the speakers are Jun Ogawa (Kyoto University), Jun Kunisawa (National Institutes of Biomedical Innovation, Health and Nutrition Osaka, Japan), and Ikuo Kimura (Tokyo University of Agriculture and Technology, Fuchu, Japan). The webinar is an excellent

Continue reading »
NOSTER is our strategic brand

The ‘NOSTER’ brand. The NOSTER brand underscores the desire of all the staff at Nitto Pharma—an innovative biopharmaceutical company based in Kyoto, Japan—to contribute to the treatment of people suffering from diseases. Nitto Pharma has continued to conduct research and development of microorganisms since 1947 in cooperation with many kinds of universities and research institutes based on

Continue reading »
Nitto Pharma headquarters is located in a leafy and spacious environment

Nitto Pharma Headquarters, Kyoto. Nitto Pharma is located in a quiet residential area about 30-minutes by train from Kyoto Station. The company is surrounded by narrow cobbled streets lined with Sakura trees and the view from the entrance of the company’s premises is one of carefully mown lawns surrounded by many varieties of flowers and

Continue reading »
Clinical application of postbiotics in the treatment of Helicobacter infections

Liquid HYA HYA-fatty acid combats bacterial gastric diseases in mouse model experiments The human digestive system is host to many kinds of bacteria: some friendly, probiotics types, and other kinds that are harmful. Identifying metabolic processes that can differentiate between these two types of bacteria is important to develop treatments for diseases caused by unfriendly

Continue reading »
Advances in postbiotics research for healthcare

Graph showing changes in blood glucose level in all subjects after ingestion. Clinical trials with fatty acid (HYA) derived from probiotic bacteria show potential health benefits in treating metabolic disorders Metabolic syndrome is a set of conditions including obesity and hypertension that could potentially lead to heart disease and diabetes. Reported cases of metabolic syndrome

Continue reading »
Nitto Pharma participates at The American Oil Chemists’ Society (AOCS) meeting, 6-9 May 2018, Minneapolis Convention Center, Minneapolis, Minnesota, USA.

Nitto Pharma representative presenting the company’s research at AOCS. Nitto Pharma participates at The American Oil Chemists’ Society (AOCS) meeting, 6-9 May 2018, Minneapolis Convention Center, Minneapolis, Minnesota, USA. In a presentation entitled, ‘Effect of the Intake of a Gut Microbial Linoleic Acid Metabolite, 10-hydroxy-cis-12octadecenoic Acid (HYA), on Postprandial Hyperglycemia’, Nitto researchers describe the results

Continue reading »
Kohey Kitao / Managing Director and Head of R&D, Nitto Pharma

Kohey Kitao Managing Director and Head of R&D, Nitto Pharma Kohey Kitao is the Managing Director and Head of R&D at Nitto Pharma, Kyoto. “I manage the entire research pipeline of Nitto Pharma,” says Kitao. “Nitto Pharma is a pharmaceutical manufacturer founded in 1947. We are engaged in medicine and food development based on research

Continue reading »
Yasunori Yonejima / Research Scientist, Nitto Pharma

Yasunori Yonejima Research Scientist, Nitto Pharma Yasunori Yonejima and colleagues are conducting research on useful microorganisms such as lactic acid bacteria. “We have already commercialized four species of lactic acid bacteria, bacillus natto, butyric acid bacteria and bifidobacteria as probiotics,” says Yonejima. “We are still searching for new active bacteria as a life work.” In

Continue reading »